ArticleEcancermedicalscience2025
Patterns and prognostic factors of metastasis in Latino/Hispanic patients with melanoma and negative lymph nodes.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Malignant melanoma presents with diverse clinical and histological manifestations that vary per population. Lymph node status, assessed through sentinel lymph node biopsy, is a widely accepted standard of care and a key prognostic indicator. This study aims to identify clinical outcomes, clinicopathologic factors, recurrence patterns, metastatic spread patterns and risk factors associated with lymph node-negative melanoma in our Latino/Hispanic patient population. Methods: We included patients diagnosed with lymph node-negative melanoma at the Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru, from 2010 to 2019. Cox regression analysis was used to assess prognostic factors. Results: The study included 249 patients with lymph node-negative melanoma, with a median follow-up time of 25 months. Recurrence was observed in 27% of patients, with a mean age of 65 years compared to 60 years in the non-recurrent group. With a median follow-up of 35 months, the 3-year recurrence-free survival (RFS) rates and overall survival (OS) were 75% and 94%, respectively. The 3-year OS rate was 97% and 88% for non-recurrent and recurrent patients, respectively ( Conclusion: The Latino/Hispanic population has unique characteristics and prognostic factors for oncologic outcomes. Increased Breslow depth and number of mitoses per mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.